ArticleFrontiers in immunology2026
The evolving treatment landscape for hereditary angioedema in Sweden.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hereditary angioedema (HAE) is a rare genetic disorder, characterized by unpredictable, potentially life-threatening edema attacks. Treatment options include on-demand treatment (ODT) and long-term prophylactic (LTP) therapy. This study describes the HAE treatment landscape in Sweden, focusing on the uptake of recently reimbursed modern LTP therapies and patterns of ODT dispensation as an indirect proxy for breakthrough attacks. Methods: This nationwide, longitudinal, registry-based study utilized data from the National Prescribed Drug Register in Sweden describing all dispensed drugs with approved indications for HAE between January 2020-May 2025. Results: During 2024, 245 patients received HAE-specific drugs, with one-third dispensing LTP. Among patients with ≥12 months on modern LTP (n=69) who had at least one ODT dispensation event during their most recent 12 months of treatment (n=46/59 for lanadelumab; n=8/9 for berotralstat), the mean number of ODT packages dispensed-in addition to emergency stock ODT-was 4.3 per patient on lanadelumab and 6.5 per patient on berotralstat. Overall, 22% (n=15/69) of patients receiving modern LTP did not dispense ODT medication during their most recent 12-months of treatment. In total, 22% of patients (n=24/108) with at least one lanadelumab or berotralstat dispensation stopped dispensing modern LTP and switched to alternative LTP or ODT-only treatment options. Discussion: This study provides valuable insights into real-world dispensation patterns of HAE drugs in Sweden. Despite the availability of modern LTP therapies, there remains relatively high ODT dispensation events, suggesting ongoing unmet need and underscoring the importance of optimizing prophylactic strategies to achieve total disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.